Centre for 3D models of Health and Disease, Division of Surgery and Interventional Science, University College London, London W1W 7TY, U.K. Centre for 3D models of Health and Disease, Division of ...

A team of German scientists and biotech company Dynamic42 have jointly developed a ‘tumour-on-chip’ model of pancreatic ductal adenocarcinoma (PDAC), allowing insights into interactions between tumour ...

A team of German scientists and biotech company Dynamic42 have jointly developed a ‘tumour-on-chip’ model of pancreatic ductal adenocarcinoma (PDAC), allowing insights into interactions ...

(RTTNews) - Silexion Therapeutics (SLXN) announced positive data from preclinical studies of SIL204, its RNA interference (RNAi) therapy, in orthotopic pancreatic cancer models. These findings ...

today announced positive data from orthotopic pancreatic cancer models demonstrating that subcutaneously administered SIL204 effectively reduces both primary tumor growth and metastatic spread.

In this study, we first established two clusters that grouped pancreatic cancer cases according to their pathological characteristics and molecular markers based on PARGs. In addition, we constructed ...

AI-powered 3D object generators have revolutionized the way we create and visualize 3D models, making the process more efficient, accurate, and accessible to everyone. Whether you're a game developer, ...

Silexion Therapeutics Corp. has completed its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. SIL-204 is a next-generation siRNA candidate designed to target a broad range of ...

SIL-204's ability to reduce primary tumor growth when administered systemically in orthotopic pancreatic cancer models, where human tumor cells are implanted directly into the pancreas SIL-204's ...

Silexion Therapeutics (SLXN) announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. This milestone represents the first systematic evaluation of ...